Genetech (DNA-NYSE) posted earnings: $0.74 EPS and revenues were $2.843 Billion; expectations were $0.67 EPS & R$2.74 Billion. The stock is still at the lower end of its recent trading range of 2007. Avastin and Rituxan were more than $1 Billion combined, although there are some mixed feelings on individual drug sales from Genentech. R&D expenses grew 68% on a non-GAAP basis to $572 million year over year. We’ll have to see if they offer any new guidance in the conference call in an hour.
Jon C. Ogg
April 11, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
